Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial.
about
Molecular magnetic resonance imaging of brain-immune interactionsPreclinical and clinical research on inflammation after intracerebral hemorrhageNeuroprotection for ischemic stroke: past, present and futureIntegrin-based therapeutics: biological basis, clinical use and new drugsThe Role of the Neuroprotective Factor Npas4 in Cerebral IschemiaImmune interventions in strokeThe Yin and Yang of innate immunity in strokeCell-based therapy for ischemic strokeInflammatory responses in hypoxic ischemic encephalopathyAdhesion molecules in CNS disorders: biomarker and therapeutic targetsThe guanine-nucleotide exchange factor SGEF plays a crucial role in the formation of atherosclerosisCell tracking technologies for acute ischemic brain injuryInflammation and infection in clinical strokeTargeting leukocyte integrins in human diseasesNeuroinflammation and cerebrovascular disease in old age: a translational medicine perspectiveThe science of cerebral ischemia and the quest for neuroprotection: navigating past failure to future successA concerted appeal for international cooperation in preclinical stroke researchModeling disease progression in acute stroke using clinical assessment scales.The neurovascular unit as a selective barrier to polymorphonuclear granulocyte (PMN) infiltration into the brain after ischemic injury.Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies.Should data monitoring committees assess efficacy when considering safety in trials in acute stroke?Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model.An emerging role of mast cells in cerebral ischemia and hemorrhage.Molecular dialogs between the ischemic brain and the peripheral immune system: dualistic roles in injury and repairPotential future neuroprotective therapies for neurodegenerative disorders and stroke.Inflammatory mechanisms in ischemic stroke: role of inflammatory cells.Leukocyte recruitment and ischemic brain injury.Innate inflammatory responses in stroke: mechanisms and potential therapeutic targets.Stroke management.Early release of high-mobility group box 1 (HMGB1) from neurons in experimental subarachnoid hemorrhage in vivo and in vitro.Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage.The Immune Response to Acute Focal Cerebral Ischemia and Associated Post-stroke Immunodepression: A Focused Review.Menstrual blood transplantation for ischemic stroke: Therapeutic mechanisms and practical issues.Pathophysiologic cascades in ischemic strokeRegulatory T cells modulate inflammation and reduce infarct volume in experimental brain ischaemiaTargeting the peripheral inflammatory response to stroke: role of the spleenPharmacological interventions for stroke: failures and future.Clinical trials of treatments for stroke.Neurogenesis and inflammation after ischemic stroke: what is known and where we go from here.Inhibition of junctional adhesion molecule-A/LFA interaction attenuates leukocyte trafficking and inflammation in brain ischemia/reperfusion injury.
P2860
Q21129471-119665E3-16AB-463F-96DB-221B27A433C6Q24594191-924FC73B-B561-452D-B141-5EBA9FB187CAQ24645185-6EAAF4B3-0BE8-41E8-B1E1-1D6E81CF164CQ26773026-240C265F-6649-4D07-96C3-09557480DA6FQ26774448-6FB64F62-E12F-4906-B438-ED816C931201Q26797993-2A1E63A2-CBB2-4F5B-AF20-DC1C7296844FQ26822268-C938C698-2008-4585-8923-0DAB43B3E9B9Q26827499-F942DB8A-F275-421D-92DD-FE831EF1188BQ27001711-5FDA5BB1-00BB-4F56-B7E5-29D4A852ADF9Q27015967-4FFB79FB-30B0-4EF7-9679-7BF526E1DEDFQ27317125-B4B95BA4-552C-4DDC-A66E-B887B6CADEDCQ28084529-CECB0D4A-1A9D-47B9-82E4-E60047E9DEF7Q28194382-66089D7F-F7F5-47A8-BB1D-F75ACB950FBDQ28293910-AB4C33D5-522C-44B3-B86D-FBBC70A88A13Q28393202-4D15EAAA-C2EA-4ADF-8587-44F716FBF02DQ28394257-27337783-C4E0-4FDE-8167-D2456FC0B8CFQ28658665-AD254717-5480-4D7E-A845-2DC174479219Q30497328-B3DAE43E-47B6-4F47-9365-5CA889E11287Q30536373-A6105501-0850-4423-ACAB-847DFAB61968Q31086283-4D12E552-7283-4587-9FB8-036511C6C97BQ31129891-78C26B33-E97A-4974-BA66-F7D1F1758557Q33223886-FFE1F287-D17E-4D35-A171-61433426F888Q33438542-19726A7A-0849-4EE1-BB1B-CD787C09747FQ33583258-970E48D5-3F08-4479-85C0-48379EEBFE39Q33687436-6D82F96E-C9FA-4B21-B2BE-B00120D74720Q33806613-F885EDF1-B053-4EC8-A398-B3C0A0F23AFBQ33886526-D3352883-5983-47A0-9A12-D13C8CBDCF11Q33925611-09F3B25E-24DB-4331-97AF-A33FA8B62D26Q33928297-3F700FF5-0DE7-4121-8BCB-F09EFC809D5DQ33936977-642EEEC1-E37A-466B-BBD0-5591B5DEF064Q34093771-CCC387D6-E04C-4746-87C9-9B961732D402Q34237954-0D3CEB00-1001-4BD3-8972-89CE04969DDEQ34253171-C420045E-A090-429A-9CC2-7E3E83A60713Q34282729-61742BA8-A886-4E4D-AF76-B350944AF9D8Q34311208-342A0A9D-77A5-4F7C-8C95-90144BB530FCQ34429117-6AFEF053-6007-49F8-BED9-CE4043D5DD23Q34628650-0C02BDDD-EE99-46D3-A4CA-61C7C1136A8EQ34674205-2FF3AC9F-12A4-4435-ACAC-7CE88A7281FFQ34727139-B8A2A367-043A-4542-BA55-84657D2DF419Q34754824-E0C53F26-7D0A-47A9-9D07-EE4D78AC17FF
P2860
Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Use of anti-ICAM-1 therapy in ...... Enlimomab Acute Stroke Trial.
@en
type
label
Use of anti-ICAM-1 therapy in ...... Enlimomab Acute Stroke Trial.
@en
prefLabel
Use of anti-ICAM-1 therapy in ...... Enlimomab Acute Stroke Trial.
@en
P356
P1433
P1476
Use of anti-ICAM-1 therapy in ...... Enlimomab Acute Stroke Trial.
@en
P2093
Enlimomab Acute Stroke Trial Investigators
P304
P356
10.1212/WNL.57.8.1428
P407
P577
2001-10-01T00:00:00Z